報價延遲最少15分鐘:2025/08/25 16:58 EDT
盤後時段
|
||||
|
31.18 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
30.99
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-14.90/4.94
|
|
企業價值
3.16B
|
| 資產負債 |
|
每股賬面淨值
45.10
|
| 現金流量 |
|
現金流量率
0.11
|
| 損益表 |
|
收益
2.11B
|
|
每股收益
29.06
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/08/25 16:58 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S. |
